-

Scott+Scott Attorneys at Law LLP Investigates Clover Health Investments, Corp.’s Directors and Officers for Breach of Fiduciary Duties – CLOV, IPOC

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Clover Health Investments, Corp. (“Clover Health”) (NASDAQ: CLOV); f/k/a Social Capital Hedosophia Holdings Corp. III (“SCH III”) (NYSE: IPOC) breached their fiduciary duties to SCH III and its shareholders. If you were an SCH III shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether SCH III’s board of directors or senior management failed to manage SCH III in an acceptable manner, in breach of their fiduciary duties to SCH III shareholders, and whether SCH III’s shareholders suffered damages as a result.

On January 7, 2021, SCH III closed a merger transaction, with Clover Health continuing as the successor entity. On February 4, 2021, Hindenburg Research issued a report claiming that Clover Health was misleadingly hiding governmental investigations from the public.

What You Can Do

If you were a, SCH III shareholder, you may have legal claims against SCH III’s directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.

Attorney Advertising

Scott+Scott Attorneys at Law LLP

NASDAQ:CLOV

Release Summary
Scott+Scott Attorneys at Law LLP Investigates Clover Health Investments, Corp.’s Directors and Officers for Breach of Fiduciary Duties – CLOV, IPOC
Release Versions

More News From Scott+Scott Attorneys at Law LLP

Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20...

Scott+Scott Attorneys at Law LLP Announces Parties Provide Notice of Proposed Dismissal of Defendant from Stockholder Derivative Action

WILMINGTON, Del.--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP announces that Plaintiffs in the below-entitled action concerning Meta Platforms, Inc. (META) are releasing the following notice pursuant to an order of the Delaware Court of Chancery. IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE   IN RE FACEBOOK, INC. DERIVATIVE LITIGATION   CONSOLIDATED C.A. No. 2018-0307-JTL   NOTICE OF PROPOSED DISMISSAL WITH PREJUDICE OF DEFENDANT JAN KOUM TO: ALL CURRENT STOCKHOLDERS OF META PLATFORM...

AUTODESK INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Autodesk, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADSK

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Autodesk, Inc. (“Autodesk”) (NASDAQ: ADSK) breached their fiduciary duties to Autodesk and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Autodesk’s board of directors or senior management failed to manage Autodesk in an acceptable manner, in breach of their fiduciary d...
Back to Newsroom